SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Techical Analysis
MELA
|
|
|
-2.90%
in
89 days
Broke out of trading range taking out 1 year resistance makes a nominal new high on lower volume pulled back, retested, and now starting to move up in last few sessions. Looking for higher prices with this one!
|
FDA Calendar Updates: MELA, PGNX, VPHM, WYE
MELA
|
|
|
+41.15%
in
123 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli...
|
New Indexes to Track Healthcare Trends and More
MELA
|
|
|
-3.00%
in
19 hours
(closed on 08/05/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
20 Extreme Trades on Pending FDA Decisions
MELA
|
|
|
-4.18%
in
44 days
(closed on 08/04/09)
<> Below are 20 extreme trades among companies with market caps under $500 million from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/21/09) which have pending FDA decisions for either new drug products or biological agents that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlig...
|
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, VPHM
MELA
|
|
|
-8.37%
in
17 days
(closed on 06/21/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pen...
|
From the Blogosphere
Mercer International Pops 50%, but Repros Therapeutics down 14%
|
|
|
Mercer International (MERC) 52% HIGHER; since announcing it's Q2 results on July 29, share of Mercer have skyrocketed more than 340%.
ARIAD Pharmaceuticals Inc. (ARIA) 5% HIGHER; rose after the close on Friday. This morning's report was that ARIAD and its co-plaintiffs announced that the Court of Appeals granted their petition for rehearing 'En Banc' in the Lilly NF-kB patent lawsuit. Shares were up about 2% at $2.17 as many traders sold the news.
Electro-Optical Sciences, Inc. (MELA) 19% HIGHER; was a big winner after being featured in this weekend's "unusual suspects" after Barron's highli...
|
|
By
s J
(-14.94% risk: aggressive)
08/25/09
|
Comment
|
Electro-Optical Sciences: A Speculative Stock with Great Potential
My stock suggestion today is in the spirit of adventure. It’s a medical technology company that doesn’t really have revenues, much less earnings, and it doesn’t have a product approved for sale. What it has is a great idea for a hand-held device that will enable dermatologists to scan skin lesions to determine whether they are melanomas. The company is Electro-Optical Sciences (MELA), and the device-called the MelaFind-uses light at various wave-lengths to scan the suspicious lesion. It then uses its database of melanoma images to calculate a diagnosis.
|
Unusual 11 Mid-Day Movers 2/13: MELA, BBND, GY, CSTR Higher; LYG, PNCL, AIB, WYN Lower
Electro-Optical Sciences, Inc. (NASDAQ: MELA) 68.6% HIGHER; today announced positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study, conducted at seven centers across the US, included 1,831 pigmented skin lesions from 1,383 patients, making this the largest prospective study ever conducted in melanoma detection. EOS is working to complete its Pre-Market Approval application and expects to file it with the US FDA shortly. Click here for the full repo...
|
Create Your Own Diagnostics ETF
|
|
|
With HealthShares closing shop at year-end, including the former Diagnostics fund, investors who are interested in the space can create their own ETF comprised of companies from the ETF Innovators Preventive Medicine and Emerging Diagnostics Indexes. Below is a list of companies which have stocks listed for trading in the U.S. at over $1/share with a market cap of less than $10B, focusing on smaller companies which are more leveraged to diagnostics and represent possible takeover targets for larger players such as Roche (RHHBY), Abbott Labs (ABT), and Johnson & Johnson (JNJ).
However, the sm...
|
New Preventive Medicine Index
|
|
|
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together.
With the focus on preventive medicine likely continue in the form of continued M&A...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on MELA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About ElectroOptical Sciences Inc
- Answers.com
